Loncastuximab tesirine

替朗妥昔单抗

Report date: 2026/05/12 20:00:17

Base Information

Drug NameLoncastuximab tesirine
Drug Alias NameLonca-T泰朗妥昔单抗Anti-CD19-PBD-conjugate-ADCLoncastuximab tesirine-LPYLLonca +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SG3199 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA cross linking agentsAnti-CD19
TargetsB-lymphocyte antigen CD19DNA
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaWaldenstrom MacroglobulinemiaLymphoma, Mantle-Cell +[12] 
Global Approved IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Approved Indications in ChinaLymphoma, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2021/04/23
Country/TerritoryCzechiaBelgiumCanada +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAdc Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesOverland ADCT BioPharmaOrient Europharma Co LtdFondazione Italiana Linfomi Onlus +[11] 
Inactive CompaniesADC Therapeutics (NL) BVBarbara Ann Karmanos Cancer Institute
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[7] 
Inactive IndicationsPrimary mediastinal B cell lymphomaWaldenstrom MacroglobulinemiaPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG